XIV. The rationale for combining targeted and biological anti-lymphoma drugs

Hematological Oncology

Volumn 31, Issue SUPPL 2, 2013, Pages 81-83

  Younes, Anas ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

AKT; BLK; JAK; PI3K; STAT

Indexed keywords

ANTINEOPLASTIC AGENT; CRIZOTINIB; HISTONE DEACETYLASE INHIBITOR; JANUS KINASE 2 INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;

ANAPLASTIC LYMPHOMA; ARTICLE; BURKITT LYMPHOMA; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPHOMA; MOLECULAR TARGETED THERAPY;

EID: 84879325860     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2072     Document Type: Article

References (7)

1. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nature Reviews. Clinical Oncology 2011; 8(2): 85-96.
2. Younes A, Berry DA. From drug discovery to biomarker-driven clinical trials in lymphoma. Nature Reviews. Clinical Oncology 2012; 9(11): 643-653.
3. Yang Y, Shaffer AL, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21(6): 723-737.
4. Lemoine M, Derenzini E, Buglio D, et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 2012; 119(17): 4017-4025.
5. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009; 114(14): 2926-2935.
6. Derenzini E, Lemoine M, Buglio D, et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer Journal 2011; 1(12): e46.
7. Younes A, Hagenbeek A, Coiffier B. Optimising the lymphoma response criteria in the era of targeted therapy. The Lancet Oncology 2011; 12(7): 616-617.